Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial)

BACKGROUND: Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis. A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and safety of therapy with oral alendronate (FOSAMAX;...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Chest
Hoofdauteurs: Papaioannou, Alexandra, Kennedy, Courtney C., Freitag, Andreas, Ioannidis, George, O’Neill, John, Webber, Colin, Pui, Margaret, Berthiaume, Yves, Rabin, Harvey R., Paterson, Nigel, Jeanneret, Alphonse, Matouk, Elias, Villeneuve, Josee, Nixon, Madeline, Adachi, Jonathan D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2008
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104558/
https://ncbi.nlm.nih.gov/pubmed/18641106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1378/chest.08-0608
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items